Al-Rubaish, AM;
Al-Muhanna, FA;
Alshehri, AM;
Alsulaiman, AA;
Alabdulali, MM;
Alkhamis, F;
Alamri, AS;
... Al-Ali, AK; + view all
(2021)
Prevalence of CYP2C19∗2 carriers in Saudi ischemic stroke patients and the suitability of using genotyping to guide antiplatelet therapy in a university hospital setup.
Drug Metabolism and Personalized Therapy
10.1515/dmdi-2021-0104.
(In press).
Preview |
Text
Asselbergs_10.1515_dmdi-2021-0104.pdf - Published Version Download (187kB) | Preview |
Abstract
Objectives: To mitigate the incidence of recurrent stroke in patients, dual antiplatelet therapy comprising aspirin and clopidogrel is usually administered. Clopidogrel is a prodrug and its bioactivation is catalyzed by cytochrome P450 (CYP)2C19. The main objective of this work was to determine the prevalence of CYP2C19*2 carriers in Saudi ischemic stroke patients and assess the suitability of using genotyping to guide antiplatelet therapy in a university hospital setup. // Methods: This prospective (2018–2019) study was conducted on 256 patients (age 61 ± 12.5) clinically diagnosed with ischemic stroke who were genotyped using Spartan RX CYP2C19 assay. // Results: From the total patient group (256), upon admission, 210 patients were prescribed either aspirin, clopidogrel or dual antiplatelet therapy. Of the 27 patients with the CYP2C19*2 allele who were prescribed clopidogrel (18) or dual antiplatelet therapy (9), only 21 patients could be followed up for a period of six months post stroke event, in addition to 21 age- and sex-matched patients with the normal allele. The CYP2C19*2 allele carriers had a statistically significant increased risk of recurrent stroke compared to patients carrying the normal allele. // Conclusions: This study shows the suitability of using genotyping to guide antiplatelet therapy in ischemic stroke patients in a clinical setting.
Type: | Article |
---|---|
Title: | Prevalence of CYP2C19∗2 carriers in Saudi ischemic stroke patients and the suitability of using genotyping to guide antiplatelet therapy in a university hospital setup |
Open access status: | An open access version is available from UCL Discovery |
DOI: | 10.1515/dmdi-2021-0104 |
Publisher version: | https://doi.org/10.1515/dmdi-2021-0104 |
Language: | English |
Additional information: | This version is the version of record. For information on re-use, please refer to the publisher's terms and conditions. |
Keywords: | aspirin; clopidogrel; CYP2C19*2; genotyping; stroke |
UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Health Informatics |
URI: | https://discovery.ucl.ac.uk/id/eprint/10135735 |
Archive Staff Only
![]() |
View Item |